Bain Capital Life Sciences

Bain Capital Life Sciences, founded in 2016, leverages Bain Capital's extensive history in healthcare and life sciences investing. The firm focuses on investing in biopharmaceutical, medical device, diagnostic, and life science tool companies globally, aiming to drive medical innovation and improve the lives of patients with unmet medical needs. With a team of over 25 professionals, Bain Capital Life Sciences provides strategic support to clinical and commercial-stage companies, facilitating critical phases of value creation.

Bain Capital Life Sciences

200 Clarendon Street, Boston, MA 02116, United States

https://www.baincapitallifesciences.com/

lifesciences@baincapital.com

+1 (617) 516-2000

Portfolio

Abcuro

#Biotechnology

ADARx

#Biotechnology

Alkeus Pharmaceuticals

#Biotechnology

Angitia

#Biotechnology

Annexon Biosciences

#Biotechnology

Areteia Therapeutics

#Biotechnology

Atea Pharmaceuticals

#Biotechnology

Avistone

#Biotechnology

C4 Therapeutics

#Biotechnology

Cabaletta Bio

#Biotechnology

Cardurion Pharmaceuticals

#Biotechnology

CereVasc

#Biotechnology

Cidara

#Biotechnology

Dianthus

#Biotechnology

Disc Medicine

#Biotechnology

Emalex Biosciences

#Biotechnology

FIS

#Biotechnology

Freenome

#Biotechnology

HeartFlow

#Biotechnology

Imperative Care

#Biotechnology

Invivyd

#Biotechnology

Kailera

Kailera Therapeutics is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera’s most advanced program, KAI-9531, is an injectable GLP-1/GIP receptor dual agonist that has demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China.

#Biotechnology